Reports Q3 revenue $250.4M, consensus $248.8M. “The success of Acadia’s two growing commercial franchises is clearly reflected in our third quarter 2024 results, where we delivered $250.4 million in total revenues, putting us on track to reach an impressive milestone of more than $1 billion in annualized sales in 2025,” said Catherine Owen Adams, Chief Executive Officer. “In my new role as CEO, I’m inspired and excited by the possibilities that lie ahead for Acadia, both with our current portfolio and the exciting innovations in our pipeline. The opportunity to deliver additional groundbreaking therapies to patients who need them is truly compelling. Furthermore, I see significant potential to enhance shareholder value as we continue to execute our commercial priorities and advance our pipeline assets.”
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharma sells Rare Pediatric Disease Priority Review Voucher for $150M
- ACAD Upcoming Earnings Report: What to Expect?
- Health Canada grants approval of Acadia’s Rett syndrome treatment
- Nike upgraded, PayPal downgraded: Wall Street’s top analyst calls
- Acadia Pharmaceuticals reinstated with a Market Perform at Raymond James